Immune Response to the COVID-19 Vaccine

NCT04936997 ↗

Phase 0 Completed 20 enrolled University of Arizona

NaSingle-groupOpen-labelTreatment

Summary

Explore the effects on immune response to include a potential third vaccine for the cancer cohort.

Timeline

Start: 2021-06-07
Primary completion: 2021-08-25
Completion: 2022-05-08

Outcome

Mixed primary results

paper primary outcomes were immune responses, with a secondary outcome of safety. PMID 34594036 ↗

paper 16 participants demonstrated a median threefold increase in neutralizing antibody responses, but no improvement was observed in T cell responses. PMID 34594036 ↗

Publications

Shroff RT, Chalasani P, Wei R, Pennington D, Quirk G, Schoenle MV, Peyton KL, Uhrlaub JL, Ripperger TJ, Jergovic M, Dalgai S, Wolf A, Whitmer R, Hammad H, Carrier A, Scott AJ, Nikolich-Zugich J, Worobey M, Sprissler R, Dake M, LaFleur BJ, Bhattacharya D. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nat Med. 2021 Nov;27(11):2002-2011. doi: 10.1038/s41591-021-01542-z. Epub 2021 Sep 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BNT162b2	Messenger RNA (mRNA)	—	—